Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression
Abstract Primary ovarian insufficiency (POI) is a pathological condition characterized by the early loss of functional ovarian follicles, leading to infertility and systemic consequences affecting reproductive, skeletal, cardiovascular, and neurocognitive helath. Aberrant immune activation, particul...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Cell Communication and Signaling |
| Online Access: | https://doi.org/10.1186/s12964-025-02226-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849704297821896704 |
|---|---|
| author | Guannan Zhou Yuanyuan Gu Menglei Zhang Jingxin Ding Guanming Lu Keqin Hua Fang Shen |
| author_facet | Guannan Zhou Yuanyuan Gu Menglei Zhang Jingxin Ding Guanming Lu Keqin Hua Fang Shen |
| author_sort | Guannan Zhou |
| collection | DOAJ |
| description | Abstract Primary ovarian insufficiency (POI) is a pathological condition characterized by the early loss of functional ovarian follicles, leading to infertility and systemic consequences affecting reproductive, skeletal, cardiovascular, and neurocognitive helath. Aberrant immune activation, particularly an augmented T cell response in the ovary, plays a critical role in POI pathogenesis. In this context, therapeutic modulation of immune responses through immune checkpoint ligands has garnered interest. In the present study, we identified Lamp2b as an optimal scaffold for engineering extracellular vesicles (EVs). By genetically modifying HEK-293 T-derived EVs to present PD-L1 and Gal-9, enabling them to suppress ovarian autoreactive T lymphocytes and protect ovarian cells from immune-mediated destruction. Functionally, the bioengineered nanoplatform demonstrated potent immunosuppressive effects by promoting apoptosis of effector T cells, reducing intraovarian CD8⁺ T cell infiltration and reinstating serum anti-Müllerian hormone (AMH) levels in POI models. These combined actions effectively halted disease progression, ultimately preventing POI progression and preserving ovarian function. Graphical Abstract |
| format | Article |
| id | doaj-art-bf501066893346eaa26e4bb060d6f1eb |
| institution | DOAJ |
| issn | 1478-811X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell Communication and Signaling |
| spelling | doaj-art-bf501066893346eaa26e4bb060d6f1eb2025-08-20T03:16:47ZengBMCCell Communication and Signaling1478-811X2025-05-0123111710.1186/s12964-025-02226-8Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progressionGuannan Zhou0Yuanyuan Gu1Menglei Zhang2Jingxin Ding3Guanming Lu4Keqin Hua5Fang Shen6Department of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Breast and Thyroid Surgery, Affiliated Hospital of Youjiang Medical University for NationalitiesDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityAbstract Primary ovarian insufficiency (POI) is a pathological condition characterized by the early loss of functional ovarian follicles, leading to infertility and systemic consequences affecting reproductive, skeletal, cardiovascular, and neurocognitive helath. Aberrant immune activation, particularly an augmented T cell response in the ovary, plays a critical role in POI pathogenesis. In this context, therapeutic modulation of immune responses through immune checkpoint ligands has garnered interest. In the present study, we identified Lamp2b as an optimal scaffold for engineering extracellular vesicles (EVs). By genetically modifying HEK-293 T-derived EVs to present PD-L1 and Gal-9, enabling them to suppress ovarian autoreactive T lymphocytes and protect ovarian cells from immune-mediated destruction. Functionally, the bioengineered nanoplatform demonstrated potent immunosuppressive effects by promoting apoptosis of effector T cells, reducing intraovarian CD8⁺ T cell infiltration and reinstating serum anti-Müllerian hormone (AMH) levels in POI models. These combined actions effectively halted disease progression, ultimately preventing POI progression and preserving ovarian function. Graphical Abstracthttps://doi.org/10.1186/s12964-025-02226-8 |
| spellingShingle | Guannan Zhou Yuanyuan Gu Menglei Zhang Jingxin Ding Guanming Lu Keqin Hua Fang Shen Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression Cell Communication and Signaling |
| title | Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression |
| title_full | Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression |
| title_fullStr | Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression |
| title_full_unstemmed | Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression |
| title_short | Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression |
| title_sort | identification of genetically engineered strategies to manipulate nano platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression |
| url | https://doi.org/10.1186/s12964-025-02226-8 |
| work_keys_str_mv | AT guannanzhou identificationofgeneticallyengineeredstrategiestomanipulatenanoplatformspresentingimmunotherapeuticligandsforalleviatingprimaryovarianinsufficiencyprogression AT yuanyuangu identificationofgeneticallyengineeredstrategiestomanipulatenanoplatformspresentingimmunotherapeuticligandsforalleviatingprimaryovarianinsufficiencyprogression AT mengleizhang identificationofgeneticallyengineeredstrategiestomanipulatenanoplatformspresentingimmunotherapeuticligandsforalleviatingprimaryovarianinsufficiencyprogression AT jingxinding identificationofgeneticallyengineeredstrategiestomanipulatenanoplatformspresentingimmunotherapeuticligandsforalleviatingprimaryovarianinsufficiencyprogression AT guanminglu identificationofgeneticallyengineeredstrategiestomanipulatenanoplatformspresentingimmunotherapeuticligandsforalleviatingprimaryovarianinsufficiencyprogression AT keqinhua identificationofgeneticallyengineeredstrategiestomanipulatenanoplatformspresentingimmunotherapeuticligandsforalleviatingprimaryovarianinsufficiencyprogression AT fangshen identificationofgeneticallyengineeredstrategiestomanipulatenanoplatformspresentingimmunotherapeuticligandsforalleviatingprimaryovarianinsufficiencyprogression |